Pfizer's Prevenar-13 approved in the EU
This article was originally published in Scrip
Pfizer's 13-valent pneumococcal vaccine Prevenar-13 has received an EU approval for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from six weeks to five years of age.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.